News archives


OCTOBER - DECEMBER 17

JULY - SEPTEMBER 17

APRIL - JUNE 17

JANUARY - MARCH 17

OCTOBER - DECEMBER 16

JULY - SEPTEMBER 16

APRIL - JUNE 16

JANUARY - MARCH 16

OCTOBER - DECEMBER 15

JULY - SEPTEMBER 15

APRIL - JUNE 15

JANUARY - MARCH 15

OCTOBER - DECEMBER 14

JULY - SEPTEMBER 14

APRIL - JUNE 14

JANUARY - MARCH 14

OCTOBER - DECEMBER 13

JULY - SEPTEMBER 13

APRIL - JUNE 13

JANUARY - MARCH 13

OCTOBER - DECEMBER 12

JULY - SEPTEMBER 12

APRIL - JUNE 12

JANUARY - MARCH 12

OCTOBER - DECEMBER 11

JULY - SEPTEMBER 11

APRIL - JUNE 11

JANUARY - MARCH 11

OCTOBER - DECEMBER 10

JULY - SEPTEMBER 10

APRIL - JUNE 10

JANUARY - MARCH 10

OCTOBER - DECEMBER 09

JULY - SEPTEMBER 09

APRIL - JUNE 09

JANUARY - MARCH 09

OCTOBER - DECEMBER 08

JULY - SEPTEMBER 08

APRIL - JUNE 08

JANUARY - MARCH 08

OCTOBER - DECEMBER 07

JULY - SEPTEMBER 07

APRIL - JUNE 07

JANUARY - MARCH 07

 
  current news   Press   selected story    
     
  31 October 2016  
 
Human Stem Cell-Derived Endothelial-Hepatic Platform for Efficacy Testing of Vascular-Protective Metabolites From Nutraceuticals
 
 




Authors
Balakrishnan Chakrapani Narmadaa, Yeek Teck Goha, Huan Lib, Sanjay Sinhac,d, Hanry Yube,f,g and Christine Cheunga,h

a  Institute of Molecular and Cell Biology, Proteos, Singapore
b  Institute of Bioengineering and Nanotechnology, Nanos, Singapore
c  The Anne McLaren Laboratory of Regenerative Medicine, Wellcome Trust-Medical Research Council    Cambridge Stem Cell Institute, University of Cambridge, Cambridge, United Kingdom
d  Division of Cardiovascular Medicine, Addenbrooke's Hospital, University of Cambridge, Cambridge,    United Kingdom
e  Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore,    Singapore
f  Mechanobiology Institute, Singapore
g  Singapore-MIT Alliance for Research and Technology, BioSyM, Singapore
h  Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore

Correspondence:
Christine Cheung (christine.cheung1@yahoo.com)

Published in Stem Cells Translational Medicine 7th October 2016

Abstract
Atherosclerosis underlies many cardiovascular and cerebrovascular diseases. Nutraceuticals are emerging as a therapeutic moiety for restoring vascular health. Unlike small molecule drugs, the complexity of ingredients in nutraceuticals often confounds evaluation of their efficacy in preclinical evaluation. It is recognized that liver is a vital organ in processing complex compounds into bioactive metabolites. In this work, we developed a co-culture system of human pluripotent stem cell-derived endothelial cells (hPSC-ECs) and hepatocytes (hPSC-HEPs) for predicting vascular-protective effects of nutraceuticals. To validate our model, two compounds (quercetin and genistein) known to have anti-inflammatory effects on vasculatures, were selected. We found that both quercetin and genistein were ineffective at suppressing inflammatory activation by interleukin-1β due to limited metabolic activity of hPSC-ECs. On the other hand, hPSC-HEPs demonstrated metabolic capacity to break down both nutraceuticals into primary and secondary metabolites. When hPSC-HEPs were co-cultured with hPSC-ECs to permit paracrine interactions, the continuous turnover of metabolites mitigated interleukin-1β stimulation on hPSC-ECs. We observed significant reductions in inflammatory gene expressions, nuclear translocation of nuclear factor kappa B, and interleukin-8 production. Thus, integration of hPSC-HEPs could accurately reproduce systemic effects involved in drug metabolism in vivo to unravel beneficial constituents in nutraceuticals. This physiologically-relevant endothelial-hepatic platform would be a great resource in predicting the efficacy of complex nutraceuticals and mechanistic interrogation of vascular-targeting candidate compounds.



Figure Legend:
Figure 5. Coculture with H9-embryonic stemcell-derived hepatocytes (H9-ESC-HEPs) abrogates inflammatory activation in IL-1b-stimulated H9-embryonic stem cell-derived endothelial cells (H9-ESC-ECs). (A): Schematics showing two experimental setups to study endothelial-hepatic paracrine interactions. (Bi): Immunostaining for NFkB in unstimulated and IL-1b-stimulated hPSC-ECs, treated with or without quercetin and genistein.
NFkB, red; nucleus, blue. Scale bars = 100 mm. (Bii): Quantification of NFkB nuclear translocation shows that quercetin or genistein significantly decreased levels of NFkB nuclear colocalization in coculture of hPSC-ECs with hPSC-HEPs. (C): IL-8 protein levels were significantly reduced in endothelial-hepatic coculture but not in conditionedmedia setup. Statistical differenceswere compared with their respective stimulated groups withoutnutraceutical treatment.ppp, p # .001 (n = 3 independent biological replicates).Abbreviations:hPSC-ECs, humanpluripotent stemcell-derived endothelial cells; hPSC-HEPs, human pluripotent stem cell-derived hepatocytes; IL, interleukin; NFkB, nuclear factor kB.

Read the article here

For more information on Christine CHEUNG’s lab, please click here.